

基本資料

中文姓名	林宥欣	
英文姓名	Yu-Hsin Lin	
聯絡電話	(公)02-2826700	國立陽明大學藥學系專任教授
電子信箱	ylhsin@nycu.edu.tw	

現職及與專長相關之經歷

服務機關	服務部門／系所	職稱	起訖年月
現職：			
國立陽明大學	藥學系	專任教授	2017/8-迄今
經歷：			
中國醫藥大學	生物科技學系	專任教授	2015/9-2017/7
中國醫藥大學	生物科技學系	專任副教授	2011/2-2015/8
美國德州達拉斯	西南醫學中心	訪問助理教授	2014/8 -2015/1
中國醫藥大學	教務處課務組	組長	2011/8-2013/7
中國醫藥大學	生物科技學系	專任助理教授	2007/8-2011/1
國立清華大學	化學工程學系	博士後研究員	2006/8-2007/7

研究專長

奈米藥物載體	藥物傳遞應用	奈米生物醫學	生物醫學應用
--------	--------	--------	--------

主要學歷

畢業學校	國別	主修學門系所	學位
國立清華大學	中華民國	化學工程	博士
逢甲大學	中華民國	化學工程	碩士
逢甲大學	中華民國	化學工程	學士

近五年學會和榮譽獎項

1. 中華民國生醫材料與藥物制放學會擔任副祕書長暨財務長
2. 2021年榮獲國立陽明交通大學(陽明校區)系級教學優良暨傑出教師獎項
3. 2022年臺灣綜合大學系統年輕學者創新研發成果選拔生醫組審查委員
4. 第31屆王民寧獎國內各大學院校暨學術研究機構優秀論文獎』審查委員
5. 2020年中華民國生醫材料及藥物制放學會年會籌備委員
6. 109年度臺灣綜合大學系統年輕學者創新研發成果選拔生醫組審查委員
7. 科技部生命科學研究發展司工程醫學學門醫工骨科幹細胞組複審會委員
8. 2016年榮獲李昭仁教授紀念研討會暨海峽兩岸生物醫用材料與藥物遞送研討會口頭報告年輕學者優等獎項
9. 受邀第五屆臺灣藥學聯合學術研討會給一專題演講，演講主題 Combination of targeted nanoparticles and microbubbles for enhanced tumor therapy。2022/10/29
10. 受邀至 2022 年中華民國生醫材料及藥物制放學會年會暨 科技部生科司工程醫學學門成果發表會給一專題演講
11. 受邀至 2021 年幾丁質幾丁聚醣暨生物材料研討會給一專題演講，演講主題利用多醣體於形成奈米載體在癌症治療之應用
12. 受邀至 2019 年榮陽聯合研發成果發表媒合會給一專題演講並獲得環球生技雜誌報導，演講主題奈米藥物載體用於對人類疾病之治療。
13. 指導黃研究員參加第五屆臺灣藥學聯合學術研討會之藥物科學與藥物開發組壁報論文傑出獎
14. 指導吳研究生參加第五屆臺灣藥學聯合學術研討會之藥物科學與藥物開發組壁報論文優良獎
15. 指導賴研究生參加 2021 中華民國生醫材料及藥物制放學會年會壁報論文特優獎
16. 指導許研究生參加 108 學年度陽明大學學術論文研討會海報佳作獎

近五年國際學術著作

1. Chen KW, Hsu PH, Huang HL, Liu HL, Lin YT, Hsu CY, Lin JH, **Lin YH***. Targeting nanoparticle-conjugated microbubbles combined with ultrasound-mediated microbubble destruction for enhanced tumor therapy. Pharmacological Research (2022) November 2; 186:106536. **IF 10.334** PHARMACOLOGY & PHARMACY; Ranking: 15/279 (**通訊作者**)
2. Hsiao CH, Huang HL, Chen YH, Chen ML, **Lin YH***. Enhanced antitumor effect of doxorubicin through active-targeted nanoparticles in doxorubicin-resistant triple-negative breast cancer. Journal of Drug Delivery Science and Technology (2022) October 7; 77:103845. **IF:5.062** PHARMACOLOGY & PHARMACY; Ranking: 75/279 (**通訊作者**)
3. Ho CH, Chen ML, Huang HL, Lai CJ, Liu CH, Chuu CP, **Lin YH***. Active targeting of P-selectin by fucoidan modulates the molecular profiling of metastasis in docetaxel-resistant prostate cancer. Marine Drugs (2022) August 23; 20(9): 542. **IF:6.085** CHEMISTRY, MEDICINAL; Ranking: 10/63 (**通訊作者**)
4. Huang SM, Wu CY, **Lin YH**, Hsieh HH, Yang HC, Chiu SC, Peng SL*. Differences in brain activity between normal and diabetic rats under isoflurane anesthesia: a resting-state functional MRI study. BMC Medical Imaging (2022) August 4; 22(1):136. **IF:2.795** RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING; Ranking: 83/163
5. Wu CY, **Lin YH**, Hsieh HH, Lin CC, Peng SL*. Sex differences in the effect of diabetes on cerebral glucose metabolism. Biomedicine (2021) November 10;9(11):1661 (SCI) **IF:6.081** PHARMACOLOGY & PHARMACY -- SCIE; Ranking: 33/275
6. Huang WY, Lai CH, Peng CL, Hsu CY, Hsu PH, Chu PY, Feng CL, **Lin YH***. Targeting tumor cells with nanoparticles for enhanced co-drug Delivery in cancer treatment. Pharmaceutics (2021) August 31; 13(9):1327. (SCI) **IF:6.321** PHARMACOLOGY & PHARMACY -- SCIE; Ranking: 29/275 (**通訊作者**)

7. Chen YA, Lai YR, Wu HY, Lo YJ, Chang YF, Hung CL, Lin CJ, Lo UG, Lin H, Hsieh JT, Chiu CH, **Lin YH***, Lai CH*. Bacterial genotoxin-coated nanoparticles for radiotherapy sensitization in prostate cancer. *Biomedicines* (2021) Feb 4;9(2):151-165. (SCI) **IF:6.081** PHARMACOLOGY & PHARMACY -- SCIE; Ranking: 33/275 (通訊作者)
8. Chen ML, Lai CJ, Lin YN, Huang CM, **Lin YH***. Multifunctional nanoparticles for targeting the tumor microenvironment to improve *synergistic drug combinations and* cancer treatment effects. *Journal of Materials Chemistry B* (2020) Dec 7;8(45):10416-10427. (SCI) **IF:6.331** MATERIALS SCIENCE, BIOMATERIALS-SCIE; Ranking: 12/40 (通訊作者)
9. Ho CH, Chu PY, Peng SL, Huang SC, **Lin YH***. The development of hyaluronan/fucoidan-based nanoparticles as macrophages targeting an epigallocatechin-3-gallate delivery system. *International Journal of Molecular Sciences* (2020) August 31, 21(17), 6327 (SCI) **IF:5.923** BIOCHEMISTRY & MOLECULAR BIOLOGY; Ranking: 67/297 (通訊作者)
10. Peng SL, Lai CH, Chu PY, Hsieh JT, Tseng YC, Chiu SC, **Lin YH***. Nanotheranostics with the combination of improved targeting, therapeutic effects, and molecular imaging. *Frontiers in Bioengineering and Biotechnology* (2020) September 8, 570490. **IF:5.890**, MULTIDISCIPLINARY SCIENCES; Ranking: 12/73 (通訊作者)
11. Chu PY, Tsai SC, Ko HY, Wu CC, **Lin YH***. Co-delivery of natural compounds with a dual-targeted nanoparticle delivery system for improving synergistic therapy in an orthotopic tumor model. *ACS Applied Materials and Interfaces* (2019) July 11(27):23880-23892 (SCI) **IF:9.229**; MATERIALS SCIENCE, MULTIDISCIPLINARY; Ranking: 44/333 (通訊作者)
12. Chen YH, Tsai WH, Wu HY, Chen CY, Yeh WL, Chen YH, Hsu HY, Chen WW, Chen YW, Chang WW, Lin TL, Lai HC, **Lin YH***, Lai CH*. Probiotic *Lactobacillus* spp. act against *Helicobacter pylori*-induced inflammation. *Journal of Clinical Medicine* (2019) January 8(1):90. (SCI) **IF:4.241**; MEDICINE, GENERAL & INTERNAL-SCIE; Ranking: 39/169 (通訊作者)
13. Mi FL, Wang LF, Chu PY, Peng SL, Feng CL, Lai YJ, Li JN, **Lin YH***. Active tumor-targeted co-delivery of epigallocatechin gallate and doxorubicin in nanoparticles for combination gastric cancer therapy. *ACS Biomaterials Science & Engineering* (2018) July 4(8):2847-59. (SCI) **IF:4.749**; MATERIALS SCIENCE, BIOMATERIALS-SCIE; Ranking: 17/40 (通訊作者)
14. **Lin YH**, Lu KY, Tseng CL, Wu JY, Chen CH, Mi FL*. Development of genipin-crosslinked fucoidan/chitosan-N-arginine nanogels for antibiotic delivery to treat *Helicobacter pylori* infection. *Nanomedicine* (2017) June 12(12):1491-510. (SCI) **IF: 5.307**; BIOTECHNOLOGY & APPLIED MICROBIOLOGY; Ranking: 30/159 (第一作者)
15. **Lin YH***, Lin JH, Hong YS. Development of chitosan/poly- γ -glutamic acid/pluronic/curcumin nanoparticles in chitosan dressings for wound regeneration. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* (2017) January 105(1):81-90. (SCI) **IF:3.368**; ENGINEERING, BIOMEDICAL; Ranking: 43/90 (第一暨通訊作者)
16. Huang WY, Lin JN, Hsieh JT, Chou SC, Lai CH, Yun EJ, Lo UG, Pong RC, Lin JH, **Lin YH***. Nanoparticle targeting CD44-positive cancer cells for site-specific drug delivery in prostate cancer therapy. *ACS Applied Materials and Interfaces* (2016) November 16;8(45):30722-30734. (SCI) **IF:9.229**; MATERIALS SCIENCE, MULTIDISCIPLINARY; Ranking: 44/333 (通訊作者)
17. **Lin YH***, Lin JH, Li TS, Wang SH, Yao CH, Chung WY, Ko TH. Dressing with epigallocatechin gallate-nanoparticles for wound regeneration. *Wound Repair and Regeneration* (2016) March 24(2):287-301. (SCI) **IF:3.617**; SURGERY; Ranking: 51/212 (第一暨通訊作者)
18. **Lin YH***, Hsu WS, Chung WY, Ko TH, Lin JH. Silver-based wound dressings reduce bacterial burden and promote wound healing. *International Wound Journal* (2016) August 3(4):505-511. **IF:3.315**; SURGERY; Ranking: 67/212 (第一暨通訊作者)

近五年通過專利

1. 一種乳酸菌組合物用于抑制欲於胃幽門螺旋桿菌引發的胃炎及其用途
2. 一種益生菌組合物及其抑制胃幽門螺旋桿菌吸附之用途
3. Attestato di brevetto per invenzione industriale
4. Lactobacillus composition for inhibiting gastritis induced by gastric Helicobacter Pylori and use thereof
5. Method for reducing radio-resistance of prostate cancer cells and/or treating prostate cancer
6. 降低前列腺癌細胞對放射線之抗性及／或治療前列腺癌之藥劑及其應用

近五年研究計畫

1. 國科會產學計畫-新型奈米載體平台用於傳遞功效性益生菌治療癌症之開發應用 (2022/6/1~2023/5/31)
2. 國科會計畫-口服奈米劑型對鄰苯二甲酸 2-乙基己基酯(塑化劑)引起胃癌惡化之治療及機制研究 (2021/8/1~2024/7/31)
3. 國科會計畫-超音波技術調控細胞抗藥蛋白表現與奈米藥物載體用於提升治療抗藥性三陰性乳癌之策略 (2021/8/1~2022/7/31)
4. 亞東醫院與陽明大學計畫-提高對抗藥性三陰性乳癌腫瘤之治療效果新策略-奈米藥物載體技術(2021//1~2021/12/31)
5. 振興醫院與陽明大學計畫-結合超音波技術和具標靶奈米藥物載體於促進抗藥性癌症對藥物治療效用性(2020//1~2020/12/31)
6. 振興醫院與陽明大學計畫-開發具藥物協同作用之雙標靶奈米藥物載體於降低藥物被排除之前列腺癌應用(2019//1~2019/12/31)
7. 國科會計畫-以標靶奈米藥物載體控制藥物被排除之超音波藥物制放用於抑制腫瘤生長研究 (2018/8/1~2021/7/31)
8. 國科會計畫-開發新型結合雙重標靶和雙階段藥物釋放之奈米藥物載體於治療前列腺癌症和抑制癌症轉移應用 (2017/8/1~2020/7/31)
9. 國科會計畫-可承載 epigallocatechin-3 gallate 藥物多功能性奈米載體於標靶性治療胃癌腫瘤之應用 2015/8/1~2017/7/31)

近五年研討會資料

1. Hau-Lun Huang (黃浩綸), Yi-Ting Wu (吳依庭), Yu-Hsin Lin (林宥欣)*. Doxorubicin-loaded Nanoparticles enhanced its anticancer effects through active targeted drug-resistant triple-negative breast cancer cells. 第五屆臺灣藥學聯合學術研討會.
2. Yi-Ting Wu (吳依庭), Hau-Lun Huang (黃浩綸), Yu-Hsin Lin (林宥欣)*. Fucoidan combined with docetaxel actively targets P-selectin as a potential chemotherapeutics for docetaxel-resistant prostate cancer. 第五屆臺灣藥學聯合學術研討會.
3. Hau-Lun Huang (黃浩綸), Yong-Xin Ta (鄭詠馨), Yi-Ting Wu (吳依庭), Yu-Hsin Lin (林宥欣)*. Active targeted nanoparticles enhanced anticancer effects of doxorubicin on drug-resistant triple negative breast cancer cells. 2022 中華民國生醫材料及藥物制放學會年會暨 科技部生科司工程醫學學門成果發表會.
4. Yi-Ting Wu (吳依庭), Hau-Lun Huang (黃浩綸), Yu-Hsin Lin (林宥欣)*. Active targeting P-selectin via fucoidan-combined docetaxel is a potential chemotherapeutics for docetaxel-resistant prostate cancer. 2022 中華民國生醫材料及藥物制放學會年會暨 科技部生科司工程醫學學門成果發表會
5. Ting-Fang Lai 賴廷芳, Yi-Ting Wu 吳依庭, Che-Yu Hsu 許哲瑜, Yu-Hsin Lin 林宥欣*. Ultrasound triggers targeted nanoparticles conjugated with microbubble to improve gastric cancer

therapy. 2021 中華民國生醫材料及藥物製劑學會年會暨 2021 科技部生科司工程醫學學門成果發表會

6. Chiun-Wei Huang 黃群偉, Shao-Chieh Chiu 邱劭傑, Yen-Chun Tseng 曾彥鈞, Yu-Hsin Lin 林宥欣*. Development of a novel nanoparticle in combination with dual-targeting and therapeutic drug delivery platform for the treatment prostate cancer and inhibition of cancer metastasis. 2021 中華民國生醫材料及藥物製劑學會年會暨 2021 科技部生科司工程醫學學門成果發表會
7. Che-Yu Hsu 許哲瑜, Po-Hung Hsu 許博泓, Chun-Lung Feng 馮俊龍, Yu-Hsin Lin 林宥欣*. Targeted nanoparticles that control drug exclusion from cells by using ultrasound-drug release for tumor growth inhibition. 2021 年生物醫學工程科技研討會
8. Ling-Yu Wang 王菱渝, Che-Yu Hsu 許哲瑜, Ting-Fang Lai 賴廷芳, Yu-Hsin Lin 林宥欣*. Targeted nanoparticles conjugated with microbubble for drug delivery by ultrasound in gastric cancer therapy. 2020 年第二屆臺灣藥學聯合學術研討會. 2020/11/08。MOST 107-2221-E-010-004-MY3.
9. Yi-Hsuan Chen 陳宜璇, Shun-Chih Huang 黃順志, Mei-Lin Chen 陳美鈴, Yu-Hsin Lin 林宥欣*. Development of a dual targeting nanoparticle in combination with drug synergy and reduce drug exclusion from cells in prostate cancer application. 2020年第二屆臺灣藥學聯合學術研討會
10. Che-Yu Hsu 許哲瑜, Po-Hung Hsu 許博泓, Yu-Hsin Lin 林宥欣*. Targeted Nanoparticles Conjugated with Microbubble for Drug Delivery by Ultrasound in Gastric Cancer Therapy. 108 學年度陽明大學學術論文研討會
11. Yu-Hsin Lin*, Pei-Yi Chu and Han-Yu Ko. Dual-targeted nanoparticle delivery system for improving drug synergistic therapy in orthotopic prostate tumor model. MNC 2019 32nd International Microprocesses and Nanotechnology Conference, International Conference Center Hiroshima, Hiroshima, Japan. 2019/10/28~2019/10/31
12. 林宥欣 Yu-Hsin Lin*, 許博泓 Po-Hung Hsu, 馮俊龍 Chun-Lung Feng, 許哲瑜 Che-Yu Hsu. 以標靶奈米藥物載體控制藥物被排除之超音波藥物製劑用於抑制腫瘤生長研究 (1/3). 「The 9th WACBE World Congress in Bioengineering」 台灣大學
13. 許哲瑜, 黃順志, 林宥欣*. 利用超音波控制結合微氣泡之標靶奈米載體於遞送藥物至胃癌腫瘤治療. 108年台灣藥學會年會暨學術研討會. 台北醫學大學. 2019/12/14
14. 許哲瑜 Che-Yu Hsu, 陳繼芸 Chi-Yun Chen, 朱珮儀 Pei-Yi Chu, 馮俊龍 Chun-Lung Feng, 賴盈靜 Ying-Jing Lai, 林宥欣 Yu-Hsin Lin*. 標靶性奈米藥物載體於共遞送兒茶素沒食子酸酯與阿黴素藥物對胃癌腫瘤治療. 第三十四屆生物醫學聯合學術年會
15. 陳繼芸 Chi-Yun Chen, 邱劭傑 Shao-Chieh Chiu, 朱珮儀 Pei-Yi Chu, 許哲瑜 Che-Yu Hsu, 曾彥鈞 Yen-Chun Tseng, 黃群偉 Chiun-Wei Huang*, 林宥欣 Yu-Hsin Lin*. Development of a Novel Nanoparticle in Combination with Dual Targeting and Therapeutic Drug Delivery Platform for The Treatment Prostate Cancer and Inhibition of Cancer Metastasis. 第三十四屆生物醫學聯合學術年會
16. 林宥欣 Yu-Hsin Lin*, 林佺男 Yi-Nan Lin, 馮俊龍 Chun-Lung Feng. 可承載 epigallocatechin-3 gallate 藥物多功能性奈米載體於標靶性治療胃癌腫瘤之應用 (3/3) 「2017 生物醫學工程科技研討會暨科技部醫學工程學門成果發表會」

奈米生醫實驗室



林宥欣 (Yu-Hsin Lin) 教授


專長: 奈米藥物載體、藥物傳遞應用、奈米生物醫學、生物醫學應用

Office: 守仁大樓 707室


Phone: 02-2826-7932

Email: ylhsin@nycu.edu.tw


奈米藥物
載體平台



Gastric Ulcer




Prostate Cancer




口服
&
注射
途徑

Gastric Cancer






Breast Cancer




Gastric Ulcer Therapy

Prepared targeting *H. pylori* genipin-fucose-chitosan/heparin nanoparticles






- : Fucose-chitosan
- : Heparin
- : Genipin
- : Amoxicillin




Particle size : 241.3 ± 2.6 nm
Polydispersity index : 0.24 ± 0.05

Zeta potential value
32.1 ± 1.7 mV




In vitro: nanoparticles for inhibited *Helicobacter pylori* ability analysis







Scanning electron microscopy





Transmission electron microscopy



Gastric Cancer Therapy













Enhancement of US image by microbubble-conjugated nanoparticle



Prostate Ulcer Therapy


EGCG-loaded FU/HA/PG-c-PLGA/IO NPs




Orthotopic SCID Mice Model of Human Prostate Cancer




After orthotopic prostate tumor surgery observation




A Orthotopic prostate cancer xenograft mouse model




B Normal mouse model




C Bioluminescent expression prostate tumor



Near infrared fluorescent VivoTag 750 labeled NPs




Superimposition



Breast Ulcer Therapy

Enhanced antitumor effect of DOX through targeted nanoparticles in DOX-resistant TNBC



Fluorescence distribution images of nanoparticles were captured using CLSM and antitumor effects of different samples in orthotopic breast tumor

